Synergy Pharmaceuticals is a biopharmaceutical company specializing in the development of new drugs to treat gastrointestinal disorders and diseases. The company’s proprietary drug candidate is plecanatide, a synthetic analog of the human gastrointestinal hormone uroguanylin. Plecanatide has been undergoing studies and clinical trials for the treatment of chronic idiopathic constipation, and the drug is also being developed for the treatment of constipation-predominant irritable bowel syndrome. For more information, visit the company’s Web site at www.synergypharma.com

ROTH Capital Partners is a relationship-driven investment bank that primarily focuses on connecting small-cap publicly traded companies with institutional investors. This year’s annual ROTH conference will take place at The Ritz Carlton located in Dana Point, CA, on March 11-14. Bringing together executives from more than 400 growth companies, the 24th Annual ROTH Conference is one of the largest of its kind in the U.S. For more information on ROTH Capital Partners, visit www.roth.com

Let us hear your thoughts below: